Acknowledgements: We thank Albert Falch, Verena Pittl, Maria Huber, Anna Sauerwein, Anne Heberle, and Toni Rabensteiner for excellent technical and organizational support. We thank Prof. Florian Krammer and Prof. Viviana Simon for sharing their Delta isolate and Prof. Oliver T. Keppler and Dr. Marcel Stern for sharing their Gamma isolate with us. The European Union’s Horizon 2020 research and innovation program under grant agreement No. 101016174 and the Austrian Science Fund (FWF) with project number P35159-B supported J.K. The NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program supported J.K., D.S., and A.N. A.N. was supported by the Gates Cambridge Trust.Funder: European Union’s Horizon 2020 research and innovation program under grant agreement No. 101016174 NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE programFunder: Gates Cambridge Trust; doi: https://doi.org/10.13039/501100005370Since emergence of the initial SARS-CoV-2 BA.1, BA.2 and BA.5 variants, Omicron has diversified substantially. Antigenic characterization of these new variants is important to analyze their potential immune escape from population immunity and implications for future vaccine composition. Here, we describe an antigenic map based on human single-exposure sera and live-virus isolates that includes a broad selection of recently emerged Omicron variants such as BA.2.75, BF.7, BQ, XBB and XBF variants. Recent Omicron variants clustered around BA.1 and BA.5 with some variants further extending the antigenic space. Based on this antigenic map we constructed antibody landscapes to describe neutralization profiles after booster immunization with bivalent mRNA vaccines based on ancestral virus and either BA.1 or BA.4/5. Immune escape of BA.2.75, BQ, XBB and XBF variants was also evident in bivalently boosted individuals, however, cross-neutralization was improved for those with hybrid immunity. Our results indicate that future vaccine updates are needed to induce cross-neutralizing antibodies against currently circulating variants
